Key result
CABG may benefit ischemic HFrEF patients over OMT, while PCI shows inconsistent results.
Why the study?
Despite advances in optimal medical treatment, the additional benefit of coronary revascularization in patients with ischemic HFrEF remains uncertain, and evolving medical therapy complicates the interpretation of previous studies.
Does coronary revascularization improve outcomes in patients with ischemic heart disease and HFrEF compared to optimal medical treatment?
Population
Patients with ischemic heart disease and HFrEF
Comparison
Coronary revascularization vs optimal medical treatment
Design
Review
Authors
Loading...
Cautions against routine PCI in ischemic HFrEF on OMT; leaves open revascularization benefit pending contemporary trials.
Does coronary revascularization improve outcomes in patients with ischemic heart disease and HFrEF compared to optimal medical treatment?
This review highlights the uncertain benefit of coronary revascularization, particularly PCI, in patients with ischemic HFrEF on modern optimal medical therapy, emphasizing the need for contemporary clinical trials.
Lacalle et al. (2026) studied this question. Coronary revascularization, especially CABG, may benefit HFrEF patients with ischemic heart disease, but PCI benefits are inconsistent, needing further trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: